Received Feb 21, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
never got her second dose; she was sick; not feeling good; This non-serious case was reported by a consumer via call center representative and described the occurrence of sickness in a adult female patient who received Herpes zoster (Shingrix) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis. Previously administered products included COVID vaccine (had COVID vaccines prior to receiving Shingrix (no product information provided)). In NOV-2022, the patient received the 1st dose of Shingrix. On an unknown date, the patient received Shingrix. In NOV-2022, less than a day after receiving Shingrix and not applicable after receiving Shingrix, the patient experienced sickness (Verbatim: she was sick) and feeling unwell (Verbatim: not feeling good). On an unknown date, the patient experienced incomplete course of vaccination (Verbatim: never got her second dose ). The outcome of the sickness and feeling unwell were resolved and the outcome of the incomplete course of vaccination was unknown. It was unknown if the reporter considered the sickness and feeling unwell to be related to Shingrix. It was unknown if the company considered the sickness and feeling unwell to be related to Shingrix. Additional Information: GSK receipt date: 12-FEB-2025 Patient reported that she received her first dose of Shingrix in November 2022 and never got her second dose. Patient also reported that starting the day after the first dose of Shingrix, she was sick and not feeling good, and this lasted for a few days. Patient also stated that she had Covid vaccines prior to receiving Shingrix, no product information provided. The patient did not had Lot/Expiry/Location of Administration to provide. Till the time of reporting patient did not received 2nd dose of Shingrix, which led to incomplete course of vaccination.